Week in Medicine News and Research

RSS
Early trial results in lung cancer

Early trial results in lung cancer

LUX-Lung 8 supports afatinib in squamous NSCLC

LUX-Lung 8 supports afatinib in squamous NSCLC

EGFR–TKI response worse in NSCLC patients with rare EGFR mutations

EGFR–TKI response worse in NSCLC patients with rare EGFR mutations

Chemotherapy plus radiation improves survival in R1 NSCLC patients

Chemotherapy plus radiation improves survival in R1 NSCLC patients

Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

VATS lobectomy best for NSCLC patient short-term outcomes

VATS lobectomy best for NSCLC patient short-term outcomes

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

SRS fails to improve survival for NSCLC brain metastases patients

SRS fails to improve survival for NSCLC brain metastases patients

LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 shows QoL, symptoms benefits

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

MET amplified in NSCLC irrespective of type, genetic background

MET amplified in NSCLC irrespective of type, genetic background

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Postop chemotherapy supported for stage III NSCLC

Postop chemotherapy supported for stage III NSCLC

Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC